Pfizer said in a press release that in a late-stage trial of more than 2,200 adolescents in the United States, none of the vaccinated people were infected with COVID-19. The results indicate that the Pfizer-BioNTech vaccine may be more effective in people between 12 and 15 years of age than in adults.
Pfizer has not yet released test data. The company’s chief executive, Albert Bourla, said that the company plans to submit the results to the FDA in the next few weeks and “hopes to start vaccinating this age group before the start of the next school year.”
If emergency authorization is obtained, Pfizer’s vaccine will be the first vaccine in the United States for children under 16 years of age.Public health expert Believe Vaccination of children is essential to achieve “herd immunity”-when so many people are immune to COVID-19, the virus will no longer spread effectively. If, as announced by Pfizer, the test results show that the vaccine is indeed safe and effective, President Joe Biden has called for immunizations for high school students before the fall of the United States and for elementary school students in early 2022.
Pfizer said the trial showed that the vaccine is safe in children aged 12 to 15, and its side effects “usually are consistent with those observed by participants aged 16 to 25.”
Pfizer’s vaccine First authorized for emergency use Targeting people over the age of 16 in December, more than 75 million doses have been administered to Americans since then.A kind Clinical Trials It was discovered last fall that it was 95% effective in reducing adult COVID-19 infection; a recent study showed that, “real world“Since authorization.
Pfizer also stated in the announcement that it has begun vaccinating children aged 5 to 11 in a related global trial, and will start vaccinating a group of children aged 2 to 5 years old next week.